CLNNConsumer Defensive · Packaged FoodsThe 5 Wall Street analysts covering Clene, Inc. hold a median 12-month price target of $30 — +740.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Clene, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CLNN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +740.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 May 2026 | D. Boral Capital | Maintains | Buy | $23 |
| 4 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $31 |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 12 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Sept 2025 | Benchmark | Maintains | Buy | — |
| 21 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 May 2025 | Benchmark | Maintains | Buy | — |
| 8 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 23 Apr 2025 | Jones Trading | Initiates | Buy | — |
| 8 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLNN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Clene, Inc. returned −42.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 3% of US stocks
Cheaper than 95% of US stocks
Cheaper than 75% of US stocks
Higher than 96% of US stocks
Higher than 91% of US stocks
Higher than 73% of US stocks
Higher than 3% of US stocks
Higher than 98% of US stocks
Higher than 98% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Clene, Inc. has a market value of $46.9M and an enterprise value of $59.6M.
Revenue in the twelve months to 30 June 2026: $197K. The latest quarter grew 233.3% year on year.
Net income over the same four quarters: −$39.5M, a −20059.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$15.9M.
Trailing P/E: −1.4×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Clene, Inc. employs 76 people — $3K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Clene, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Clene Inc. announced that its management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. conference in September. The company made the announcement on September 3, 2026.
Why it matters — Presentations at investor conferences give Clene management a platform to share updates with the investment community, so CLNN watchers may gain insight into the company's outlook.
Clene is preparing to submit a New Drug Application seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, after completing additional biomarker analyses requested by the FDA. CEO Rob Etherington confirmed the plan in an interview.
Why it matters — A CLNN watcher would care because a planned NDA submission marks a key regulatory step for the company's lead ALS candidate, CNM-Au8.
Clene Inc. announced that management will present at the Emerging Growth Conference, a virtual event scheduled for August 19, 2026, at 3:10 p.m. The company disclosed the date and time of the presentation.
Why it matters — A CLNN watcher would care because the company presentation offers an opportunity to hear directly from management about Clene's business and outlook.
Clene Inc. reported a Q2 quarterly loss of $0.60 per share, wider than the Zacks Consensus Estimate of a $0.37 loss. The latest loss was narrower than the $0.78 per share loss recorded in the same quarter a year earlier, while revenue beat estimates.
Why it matters — The results show the company missed analyst earnings expectations for the quarter despite improving year-over-year, which is relevant to investors tracking Clene's financial trajectory.
Clene reported its second quarter 2026 financial results and said it expects to submit a New Drug Application for CNM-Au8 in ALS under the accelerated approval pathway in early Q4 2026, citing survival and functional benefit in patients whose NfL levels declined or stabilized.
Why it matters — A CLNN watcher would care because a planned NDA submission in early Q4 2026 represents a major regulatory milestone for the company's lead ALS candidate, CNM-Au8, under the accelerated approval pathway.
The 5 Wall Street analysts covering Clene, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Clene, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Clene, Inc. 26 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 11 Sept 2026, Clene, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +740.3% from the last close, and Ticker Nerd's factor model ranks Clene, Inc. 26 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Clene, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLNN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $50 over the next 12 months.
Clene, Inc. returned -42.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases.
The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Clene to Present at Upcoming September Investor Conferences". Clene Inc. announced that its management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. conference in September. The company made the announcement on September 3, 2026.
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. Clene Inc. develops oral nanotechnology-based drug candidates designed to support neuronal health and function, with programs centered on conditions such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. Its current portfolio includes investigational therapies and related platform technologies aimed at improving mitochondrial function, protecting neurons, and supporting remyelination. The company also operates activities in dietary supplements, leveraging its nanocrystal manufacturing capabilities to produce low-concentration supplement products. Headquartered in Salt Lake City, Utah, Clene Inc. plays a specialized role in the pharmaceutical market by advancing novel approaches for central nervous system disorders and related neurological conditions.
CEO Mr. Robert Etherington MBA · 76 employees · United States · https://clene.com
